$LFST

LifeStance Health Group, Inc. (LFST): Results of Operations and Financial Condition

LifeStance Health Group, Inc. (LFST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lfst-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Investor Relations Contact Monica Prokocki VP of Finance & Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook Announc

Original reporting
Published Aug 6, 2026, 12:21 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 10:35 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$LFST
Bullish
high confidence
Mentioned
$LFST
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LFSTBullishHigh
01

Why it matters

The filing provides a complete earnings-and-guidance package plus a new $100M share repurchase authorization, which can drive both fundamental repricing and near-term sentiment.

02

Market read

Traders can update models immediately using the disclosed Q2 metrics, FY2026 guidance ranges, and Q3 outlook, and assess capital return via the repurchase program.

03

What to watch

Net long-term debt of $259.0M and the pace of free cash flow conversion versus repurchase execution could matter for valuation and credit risk.

Relevance 7/10Novelty 9/10Timing: pre-market/early trading after the Aug 6, 2026 8-K and earnings release

Background

This is an SEC 8-K (Item 2.02) with LifeStance’s Q2 2026 results, cash flow/capital allocation updates, and updated 2026 outlook.

Company-level read

Ticker impact

$LFSTBullishHigh confidence
Context

LifeStance reported Q2 revenue of $435.4M (+26% YoY), net income $23.6M, and raised FY2026 guidance plus a $100M buyback.

Expected impact

Near-term upside bias as traders price in higher 2026 profitability and capital return; follow-through depends on Q3 guide range.

Evidence & confidence

The filing discloses multiple fresh, decision-relevant datapoints: quarterly results, explicit FY and Q3 guidance ranges, and a board-approved $100M repurchase program.

Market effects

Signals improving operating leverage and profitability trajectory for outpatient mental healthcare operators, potentially affecting read-across sentiment.

No specific regional catalyst beyond nationwide center footprint expansion.

Primarily US-focused healthcare services; limited direct global market linkage.

Counterpoint

Guidance raises expectations, but the Q3 revenue and Adjusted EBITDA ranges could still disappoint if visit growth or center margin trends slow.

Key entities

  • LifeStance Health Group, Inc.

    Outpatient mental healthcare provider reporting Q2 2026 results and raising FY2026 guidance; authorizes up to $100M share repurchases.

  • Dave Bourdon

    CEO quoted on the quarter’s performance and growth outlook.

Related articles

$LFSTMedAI 8/10

LifeStance Health Group, Inc. Q2 2026 Earnings Call Summary

LifeStance Health Group reported Q2 2026 revenue growth of 26%, driven by higher visit volumes and a 6% rise in revenue per visit, and said visits per clinician rose 7% YoY. The company raised full-year 2026 guidance to $1.685B-$1.725B revenue and 13.2% adjusted EBITDA margins, approved a new $100M buyback, and reported Q2 free cash flow of $88M.

$LFSTHighAI 9/10

LifeStance (LFST) Q2 2026 Earnings Call Transcript

LifeStance (LFST) reported Q2 2026 results on an earnings call. Revenue rose to $435 million (+26%) on 2.6 million visits (+19%) and total revenue per visit of $167 (+6%). Adjusted EBITDA was $66 million (+94%) with a 15.2% margin. Full-year 2026 revenue guidance was raised to $1.685-$1.725 billion and adjusted EBITDA to $215-$235 million.

$LFSTMedAI 8/10

LifeStance Health: Q2 Earnings Snapshot

LifeStance Health Group Inc. (LFST) reported Q2 net income of $23.6 million, or 6 cents per share, topping Wall Street expectations. Revenue was $435.4 million versus an expected $414.3 million, according to Zacks Investment Research. For the quarter ending September, the company forecast revenue of $420 million to $440 million, and full-year revenue of $1.69 billion to $1.73 billion.

$SHOPMedAI 8/10

Shopify Was Supposed to Be an AI Casualty. Its AI-Referred Traffic Just Tripled.

Shopify (SHOP) reported Q2 results, citing AI-referred traffic to merchants’ storefronts that tripled year over year and orders that began with AI search also tripled. New buyers from AI channels placed orders at nearly twice the rate of other channels. Revenue rose 34% to $3.6B, GMV reached $115.6B, operating income rose 68% to $488M, and free cash flow was $654M.

$GPRKMed

Geopark Q2 Earnings Call Highlights

Geopark (NYSE:GPRK) reported Q2 earnings call updates. It plans $40m to $50m of Vaca Muerta investment in 2H 2026 after $55m in 1H, with 70% to 80% in Q3. Full-year lifting costs are guided at $17 to $19/bbl. Cash rose to $316m, net leverage fell to 1.2x EBITDA, and a $0.023/share quarterly dividend was declared.

$GRDNMed

Guardian Pharmacy Services Q2 Earnings Call Highlights

Guardian Pharmacy Services (GRDN) reported Q2 net income of $22.1M vs $8.8M a year earlier, including an $8.5M payer-dispute settlement recorded as other income. The company expects H2 revenue to fall low-single digits YoY due to IRA pricing reductions, with adjusted EBITDA margin stable in Q3 and seasonally higher in Q4. It also appointed Morris as COO and named a new CFO.